InterCure resolves Nasdaq minimum-bid-price deficiency

InterCure ($INCR) received written confirmation that it has regained compliance with Nasdaq’s minimum-bid-price requirement. Its shares had closed at or above $1 for ten consecutive business days, allowing Nasdaq to close the specific deficiency. The decision follows an earlier warning that the shares faced delisting after the company failed to regain compliance within the original grace period.

The confirmation removes that particular listing obstacle and supersedes the bid-price issue described in the prior delisting notice. The original deficiency arose after the share price stayed below $1 for 30 consecutive business days. This is a stock-exchange compliance development, not an announcement of improved revenue, profitability or a new operating license. It also does not guarantee that the share price or future compliance will be maintained.

Sources:

• InterCure — Nasdaq compliance confirmation, issuer release